Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | LSS | P48449 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
| ▸ | F2R | P25116 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6147160 | 0.98 | GNAO1 (0.41) | GNAO1BRD4GNAI3GNAI1HRH3 | |
| SCHEMBL9666587 | 0.88 | GNAO1 (0.40) | GNAO1BRD4GNAI3GNAI1HRH3 | |
| SCHEMBL18505883 | 0.88 | SLC6A1 (0.38) | GNAO1HRH3 | |
| SCHEMBL9675370 | 0.88 | SLC6A1 (0.38) | GNAO1HRH3 | |
| SCHEMBL18505993 | 0.88 | SLC6A1 (0.38) | GNAO1HRH3 | |
| SCHEMBL9673721 | 0.86 | SIGMAR1 (0.40) | GNAO1GNAI3GNAI1HRH3SLC6A4 | |
| SCHEMBL21058885 | 0.85 | SLC6A2 (0.38) | GNAO1BRD4SLC6A4SLC6A2 | |
| SCHEMBL9728067 | 0.84 | SIGMAR1 (0.43) | GNAO1GNAI3GNAI1HRH3LSS | |
| SCHEMBL26502537 | 0.84 | DRD2 (0.40) | DRD2DRD3BCHELSS | |
| SCHEMBL9676316 | 0.81 | MEN1 (0.38) | GNAO1GNAI3GNAI1DRD3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| CN-1764661-B | Benzenesulfonamide derivatives, process for their preparation and their use for the treatment of pain | FOURNIER LAB SA | 2010-05-05 | — | — | CN | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| EP-1457488-B1 | Intermediates for use in the preparation of urea compounds having muscarinic receptor antagonist activity | THERAVANCE INC (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1606288-B1 | BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN | FOURNIER LAB SA (FR) | 2009-06-03 | — | — | EP | disclosed |
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-0703908-A1 | ANALGESIC DIBENZOXAZEPINES AND DIBENZOTHIAZEPINES | G.D. SEARLE & CO. (US) | 1996-04-03 | — | — | EP | disclosed |
| US-5461047-A | Analgesics and treats prostaglandin-E2 mediated diseases in animals | G. D. SEARLE & CO. (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1994029286-A1 | ANALGESIC DIBENZOXAZEPINES AND DIBENZOTHIAZEPINES | G.D. SEARLE & CO. (US) | 1994-12-22 | — | — | WO | disclosed |
| US-5354747-A | Analgesics | G. D. SEARLE & CO. (US) | 1994-10-11 | — | — | US | disclosed |
| EP-0306698-B1 | CONDENSED DIAZEPINONES, PROCESSES FOR THEIR PREPARATION, AND MEDICAMENTS CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1992-03-25 | — | — | EP | disclosed |
| EP-0273239-B1 | CONDENSED DIAZEPINONES, PROCESSES FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1991-03-06 | — | — | EP | disclosed |
| US-4931436-A | BRADYCARDIAL AGENTS | DR. KARL THOMAE GMBH (DE) | 1990-06-05 | — | — | US | disclosed |
| US-4873236-A | BRADYCARDIAL AGENTS | DR. KARL THOMAE GMBH (DE) | 1989-10-10 | — | — | US | disclosed |
| EP-0306698-A1 | Condensed diazepinones, processes for their preparation, and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1989-03-15 | — | — | EP | disclosed |
| EP-0273239-A1 | Condensed diazepinones, processes for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | GNAO1 290/4885BRD4 3847/4885GNAI3 472/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | GNAO1 739/4885BRD4 430/4885GNAI3 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.